. 2024 Jul 16;13(11):6473–6488. doi: 10.21037/tcr-24-245

Table 1. Summary of ADT case series studies in radio-recurrent prostate cancer.

Study	Study design	Number of patients	Primary treatment for prostate cancer [number, %]	Median follow-up duration (months)	OS results	CSS results
Garcia-Albeniz et al., 2015 (23)	Retrospective (CaPSURE)	2,096	RP [1,437, 69%]	54	Immediate ADT: 85.7% (5-yr), 69.8% (10-yr)	Immediate ADT: 95.8% (5-yr), 83.1% (10-yr)
Garcia-Albeniz et al., 2015 (23)	Retrospective (CaPSURE)	2,096	RT [659, 31%]	54	Deferred ADT: 87.7% (5-yr) 69.3% (10-yr)	Deferred ADT: 92.8% (5-yr), 84.5% (10-yr)
Fu et al., 2017 (24)	Retrospective (HCSRN)	5,084	RP [2,676]	NR	HR =0.62, 95% CI: 0.48–0.8	HR =0.65, 95% CI: 0.47–0.90
Fu et al., 2017 (24)	Retrospective (HCSRN)	5,084	RT [3,218]	NR	HR =0.62, 95% CI: 0.48–0.8	HR =0.65, 95% CI: 0.47–0.90
Duchesne et al., 2016 (25)	Prospective	293	RP or RT	60	Immediate ADT: 91.2% (5-yr)	NR
Duchesne et al., 2016 (25)	Prospective	293	RP or RT	60	Deferred ADT: 86.4% (5-yr)	NR
Klayton et al., 2011 (26)	Retrospective	432	RT only	95	PSA-DT <6: 47% (7-yr)	PSA-DT <6: 61% (7-yr)
Klayton et al., 2011 (26)	Retrospective	432	RT only	95	PSA-DT >6: 53% (7-yr)	PSA-DT >6: 85% (7-yr)

ADT, androgen deprivation therapy; OS, overall survival; CSS, cancer-specific survival; RP, radical prostatectomy; RT, radiation therapy; yr, year; NR, not reported; HR, hazard ratio; CI, confidence interval; PSA-DT, prostate-specific antigen doubling time.